TITLE

STUDIES SUPPORT LIPID SCIENCES VIRAL IMMUNOTHERAPY PLATFORM

PUB. DATE
June 2005
SOURCE
Worldwide Biotech;Jun2005, Vol. 17 Issue 6, p2
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
Reports on the presentation of the results of in vivo and in vitro studies on the Viral Immunotherapy Platform of Lipid Sciences Inc. at a symposium entitled HIV Vaccines: Current Challenges and Future Prospects, as of June 2005. Role of the study in determining a measurable immune system response to delipidated Simian Immunodeficiency Virus in infected monkeys; Comments of Lipid Sciences CEO S. Lewis Meyer on the results of the study; Information on Lipid Sciences.
ACCESSION #
17147232

 

Related Articles

  • Cancer Immunotherapy 2005: Mainz, Germany, 12–13 May 2005. Britten, C.; Gouttefangeas, C.; Kreiter, S. // Cancer Immunology, Immunotherapy;Apr2006, Vol. 55 Issue 4, p475 

    Cancer Immunotherapy 2005 was the third international meeting organized by the Association for Immunotherapy of Cancer (AIC). About 200 participants were attracted by the excellent scientific program that consisted of overview lectures from 25 international speakers in the plenary auditorium and...

  • Dendritic cells: interfaces with immunobiology and medicine. A report from the Keystone Symposia Meeting held in Keystone, 3-8 March 2003. Mohty, M.; Gaugler, B. // Leukemia (08876924);Sep2003, Vol. 17 Issue 9, p1753 

    Dendritic cells (DCs) are the most potent antigen-presenting cells in vitro and in vivo. They play a key role in the initiation of the immune response and are considered promising targets for immunotherapy. The recent DC Keystone Symposia, organized by Ralph M Steinman, Anne O'Garra and Jacques...

  • Differences in time of virus appearance in the blood and virusspecific immune responses in intravenous and intrarectal primary SIVmac251 infection of rhesus macaques; a pilot study. Stevceva, Liljana; Tryniszewska, Elzbieta; Hel, Zdenek; Nacsa, Janos; Kelsall, Brian; Parks, Robyn Washington; Franchini, Genoveffa // BMC Infectious Diseases;2001, Vol. 1 Issue 1, p1 

    Background: HIV-I can be transmitted by intravenous inoculation of contaminated blood or blood product or sexually through mucosal surfaces. Here we performed a pilot study in the SIVmac251 macaque model to address whether the route of viral entry influences the kinetics of the appearance and...

  • Development of adenoviral vector-based mucosal vaccine against influenza. Tutykhina, Irina L.; Logunov, Denis Y.; Shcherbinin, Dmitriy N.; Shmarov, Maxim M.; Tukhvatulin, Amir I.; Naroditsky, Boris S.; Gintsburg, Alexander L. // Journal of Molecular Medicine;Apr2011, Vol. 89 Issue 4, p331 

    The recent pandemic threat of the influenza virus makes the increased safety and efficiency of vaccination against the pathogen a most important issue. It has been well established that for maximum protective effect, the vaccination should mimic natural infection. Therefore, recent efforts to...

  • Oncolytic Herpes Simplex Virus Type 1 and Host Immune Responses. Fukuhara, Hiroshi; Todo, Tomoki // Current Cancer Drug Targets;Mar2007, Vol. 7 Issue 2, p149 

    The use of oncolytic herpes simplex virus type 1 (HSV-1) is a promising strategy for cancer treatment. Accumulating evidence indicates that, aside from the extent of replication capability within the tumor, the efficacy of an oncolytic HSV-1 depends on the extent of induction of host antitumor...

  • REHABILITATION OF AUTISM WITH IMMUNE MODULATION THERAPY. SINGH, Vijendra K. // Journal of Special Education & Rehabilitation;2004, Issue 3/4, p161 

    Autoimmunity may play a key role in the path ogenesis of autism, an early-onset disorder of the developing central nervous system. Viruses such as measles virus might induce autoimmunity as evidenced by a strong correlation of brain autoantibodies and measles antibodies. Autistic children also...

  • Immune control of HIV-1 after early treatment of acute infection. Rosenberg, Eric S.; Altfeld, Marcus; Poon, Samuel H.; Phillips, Mary N.; Wilkes, Barbara M.; Eldridge, Robert L.; Robbins, Gregory K.; D'Aquila, Richard T.; Goulder, Philip J.R.; Walker, Bruce D. // Nature;9/28/2000, Vol. 407 Issue 6803, p523 

    Presents a study in which treatment interruptions were administered to eight HIV-positive subjects with treated acute infection, with the plan to restart therapy if the viral load exceeded a certain level. Viral load below 5,000 RNA copies per milliliter which was acheived by all subjects;...

  • Induction of antigen-specific immune responses by dendritic cells transduced with a recombinant lentiviral vector encoding MAGE-A3 gene. Lin, Liyan; Wei, Juanbing; Chen, Yuqing; Huang, Aimin; Li, Kay; Zhang, Wenmin // Journal of Cancer Research & Clinical Oncology;Feb2014, Vol. 140 Issue 2, p281 

    Purpose: Melanoma antigen gene A3 (MAGE-A3) is aberrantly expressed in a number of cancer types. Because of its high specificity, MAGE-A3 has shown to be a promising candidate for cancer immunotherapy. Dendritic cells (DCs) have emerged as the natural agents for antigen delivery. DCs transduced...

  • Epstein-Barr virus sustains tumor killers. O'Reilly, Richard J. // Nature Medicine;Nov2008, Vol. 14 Issue 11, p1148 

    The article comments on a paper by M. A. Pule and colleagues about a strategy for T cell immunotherapy that takes advantage of the sustained immune response. According to the author, the strategy comes from the unique interactions of Epstein-Barr virus with the immune system. He adds that...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics